OncoSec Medical Inc (ONCSQ)

[guti]

yes it will, and we might get another hint soon, since in March 21, Dr. Tumeh will be speaking at the Global Technology Community meeting on Neurological Biomakers Summit. The plenary session is Novel Technologies in Biomarker Development. Dr. Tumeh has been helping PerkinElmer, UCLA and OncoSec on a collaboration to create a Patient-Selection Biomarker in Immunotherapy for almost a year.

Dr. Robert H. Pierce has previously stated: “Dr. Tumeh has demonstrated the potential of applying his highly quantitative approach to assessing the ‘stalled’ CD8+ lymphocytes, which are the key effector cells driving response to anti-PD-1 therapy. This work has the potential to identify responders from non-responders. Dr. Tumeh’s work, combined with PerkinElmer’s technology, may lead to the development of a critical diagnostic tool for identifying non-responders to anti-PD-1 monotherapy. We believe these non-responders may benefit from a combination approach of ImmunoPulse with checkpoint inhibitors, like anti-PD-1, where ImmunoPulse has the potential to convert non-responders to responders.”

GTCbio is a leading information center that provides quality forums, which facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community. Our conferences cover a variety of topics, such as stem cell therapeutics, infectious diseases, biotech partnering, pharmaceutical litigation, government regulation, bio-based chemicals and many more. Founded in 2002, GTCbio stimulates scientific discussions, offers key business insights, and promotes partnering and deal-making in the ever-changing biotech and pharmaceutical world.